Volume 7.01 | Jan 15

Prostate Cell News 7.01 January 15, 2016
Prostate Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook   PCN on Twitter
 
TOP STORY
Efficacy and Safety of Enzalutamide versus Bicalutamide for Patients with Metastatic Prostate Cancer (TERRAIN): A Randomized, Double-Blind, Phase II Study
Enzalutamide is an oral androgen-receptor inhibitor that has been shown to improve survival in two placebo-controlled Phase III trials, and is approved for patients with metastatic castration-resistant prostate cancer. The objective of the TERRAIN study was to compare the efficacy and safety of enzalutamide with bicalutamide in patients with metastatic castration-resistant prostate cancer. [Lancet Oncol] Abstract | Press Release
[Free Webinar] A Guide To Successful Flow Cytometry Analysis of ALDHbr Cells - Watch Now.
 
PUBLICATIONS (Ranked by impact factor of the journal)
LABORATORY RESEARCH

JARID1D Is a Suppressor and Prognostic Marker of Prostate Cancer Invasion and Metastasis
Scientists report that the histone H3 lysine 4 demethylase JARID1D, a male-specific protein, represses gene expression programs associated with cell invasiveness and suppresses the invasion of prostate cancer cells in vitro and in vivo. [Cancer Res] Abstract

Hypoacetylation, Hypomethylation, and Dephosphorylation of H2B Histones and Excessive Histone Deacetylase Activity in DU-145 Prostate Cancer Cells
The histone H2B of the prostate cancer cell line DU-145 was found to have hypoacetylation, hypomethylation, and dephosphorylation as compared to the non-malignant prostatic cell line RC170N/h. [J Hematol Oncol] Full Article

The Interaction between Androgen Receptor and PDGF-D in the Radiation Response of Prostate Carcinoma
Using murine PTEN-null prostate epithelial cell line and human prostate carcinoma LNCaP models, nuclear and cytosolic androgen receptor (AR) levels were determined by immunoblot analysis and the transcriptional activity of nuclear AR was assessed by RT-PCR analysis of its target genes with or without irradiation. [Prostate] Abstract

A Quinazoline-Based HDAC Inhibitor Affects Gene Expression Pathways Involved in Cholesterol Biosynthesis and Mevalonate in Prostate Cancer Cells
The anti-inflammatory and anti-cancer effects of a quinazoline epigenetic-modulator compound were determined in prostate cancer cell lines using a non-hypothesis driven transcriptomics strategy utilizing the Affymetrix PrimeView® Human Gene Expression microarray. [Mol Biosyst] Abstract | Full Article

The Canine Prostate Cancer Cell Line CHP-1 Shows Over-Expression of the Co-Chaperone Small Glutamine-Rich Tetratricopeptide Repeat-Containing Protein α
To evaluate androgen-independent neoplastic cell growth, a new canine prostate cancer cell line (CHP-1) was established in this study. CHP-1 over-expressed the co-chaperone small glutamine-rich tetratricopeptide repeat-containing protein α, which is over-expressed in human androgen-independent prostate cancer. [Vet Comp Oncol] Abstract

27-Hydroxycholesterol Stimulates Cell Proliferation and Resistance to Docetaxel-Induced Apoptosis in Prostate Epithelial Cells
Researchers determined the effect of 27-hydroxycholesterol (27-OHC) in human prostate epithelial cells RWPE-1. They found that 27-OHC stimulates proliferation and increases androgen receptor transcriptional activity. [Med Oncol] Abstract

CLINICAL RESEARCH

A Randomized Phase II Clinical Trial of Personalized Peptide Vaccination with Metronomic Low-Dose Cyclophosphamide in Patients with Metastatic Castration-Resistant Prostate Cancer
Researchers investigated the effect of metronomic cyclophosphamide in combination with personalized peptide vaccination (PPV) on regulatory T cells and myeloid-derived suppressor cells, and whether it could improve the antitumor effect of PPV. [Cancer Immunol Immunother] Abstract

Changes in Plasma Biomarkers following Treatment with Cabozantinib in Metastatic Castration-Resistant Prostate Cancer: A Post Hoc Analysis of an Extension Cohort of a Phase II Trial
Investigators performed a post hoc analysis to find associations between select plasma biomarkers and treatment response in patients with metastatic castration resistant prostate cancer who received cabozantinib 100 mg daily as part of a Phase II non-randomized expansion cohort. [J Transl Med] Full Article

A Phase II Multimodality Trial of Docetaxel/Prednisone with Sunitinib Followed by Salvage Radiation Therapy in Men with PSA Recurrent Prostate Cancer after Radical Prostatectomy
Scientists explored a novel multimodality approach of docetaxel with anti-angiogenic therapy before salvage radiotherapy. This was a Phase II single-arm prospective open-label trial with historic controls. [Prostate Cancer Prostatic Dis] Abstract

Learn More: Standardized Tools for Cancer Research
 
REVIEWS
miRNAs as Novel Biomarkers in the Management of Prostate Cancer
The authors summarize the current knowledge of microRNA (miRNA) expression patterns, as well as their targets and involvement in prostate cancer pathogenesis. [Clin Chem Lab Med] Full Article

Visit our reviews page to see a complete list of reviews in the prostate cell research field.
 
INDUSTRY NEWS
Weizmann Institute Drug, TOOKAD® Soluble, Approved for Prostate Cancer Therapy in Mexico
A therapy invented at the Weizmann Institute of Science and clinically developed in collaboration with Steba Biotech has been approved by Cofepris, Mexico’s health authority, for the focal treatment of early-stage prostate cancer. [Weizmann Institute of Science] Press Release

Historic National Coalition Formed to Accelerate Next Generation Immunotherapy in Cancer
Leaders from large pharma including Celgene and Amgen, biotech including NantWorks, NantKwest, Etubics, Altor Bioscience, and Precision Biologics, major academic cancer centers and community oncologists announced the launch of The National Immunotherapy Coalition, a historic alliance—in collaboration with Independence Blue Cross—with a singular focus: accelerating the potential of combination immunotherapies as the next generation standard of care in patients with cancer. [Business Wire] Press Release

From our sponsor:
Webinar: Brent Reynolds on the identification and characterization of neural stem cells.
Watch now.
 
POLICY NEWS
GE Healthcare, FedDev Ontario Commit CAD $40 Million for New CCRM-Led Centre to Solve Cell Therapy Manufacturing Challenges
GE Healthcare, the Federal Economic Development Agency for Southern Ontario (FedDev Ontario), and the Centre for Commercialization of Regenerative Medicine (CCRM) are building a center for advanced therapeutic cell technologies in Toronto with an investment of $40 million from GE and FedDev Ontario. [Centre for Commercialization of Regenerative Medicine] Press Release

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW ESMO Symposium on Signaling Pathways in Cancer 2016: Focusing on the HER/EGFR Family Signaling
March 4-5, 2016
Sitges-Barcelona, Spain

Visit our events page to see a complete list of events in the prostate cell community.
 
JOB OPPORTUNITIES
NEW Postdoctoral Researcher – Prostate Cancer Biology (Roswell Park Cancer Institute)

Faculty Position – Urology Research (Mayo Clinic)

Faculty Position – Cancer Biology (Michigan State University)

Post-Doc Fellowship – Cancer Stem Cell Biology (Weill Cornell Medical College)

Postdoctoral Position – Bioinformatics (Princess Margaret Cancer Centre)

Professorship – Oncogenic Pathways (German Cancer Research Center)

Professor Position – Cancer Immunotherapy (City of Hope)

Postdoctoral Research Fellow – Cell Cycle Control and Tumorigenesis (Fred Hutchinson Cancer Research Center)

Postdoctoral Positions – Prostate Cancer (Baylor College of Medicine)

Division Head – Medical Oncology (Fred Hutchinson Cancer Research Center)


Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Prostate Cell News: Archives | Events | Contact Us